These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 28502498

  • 21. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N, Hori M, Takahashi A, Ogura M, Makino H, Tamanaha T, Fujiyama H, Miyamoto Y, Harada-Shiba M.
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [Abstract] [Full Text] [Related]

  • 22. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG, Dufour R, Davignon J, Baass A.
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [Abstract] [Full Text] [Related]

  • 23. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL, Pirillo A, Norata GD.
    Vasc Health Risk Manag; 2017 Dec; 13():343-351. PubMed ID: 28919772
    [Abstract] [Full Text] [Related]

  • 24. Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain.
    Walton TA, Nishtar S, Lumb PJ, Crook MA, Marber MS, Gill J, Wierzbicki AS.
    Int J Clin Pract; 2015 Jul; 69(7):738-42. PubMed ID: 25707773
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA, Nohara A, Higashikata T, Tada H, Nakanishi C, Okada H, Konno T, Sakata K, Hayashi K, Inazu A, Mabuchi H, Yamagishi M.
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [Abstract] [Full Text] [Related]

  • 29. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V, Baratta F, Castellani V, Bartimoccia S, Nocella C, D'Erasmo L, Cocomello N, Barale C, Scicali R, Di Pino A, Piro S, Del Ben M, Arca M, Russo I, Purrello F, Carnevale R, Violi F, Pastori D, Pignatelli P.
    Int J Mol Sci; 2021 Jul 03; 22(13):. PubMed ID: 34281247
    [Abstract] [Full Text] [Related]

  • 30. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B, Gaciong Z, Hoffman P, Jankowski P, Kłosiewicz-Latoszek L, Kaźmierczak J, Mitręga K, Opolski G, Pająk A, Ponikowski P, Rynkiewicz A, Stępińska J, Średniawa B, Kalarus Z.
    Kardiol Pol; 2016 Jul 03; 74(4):394-8. PubMed ID: 27098076
    [Abstract] [Full Text] [Related]

  • 31. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S, Xu RX, Zhang Y, Guo YL, Zhu CG, Liu G, Dong Q, Li JJ.
    J Endocrinol Invest; 2015 Dec 03; 38(12):1291-9. PubMed ID: 26003826
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A case of heterozygous familial hypercholesterolemia requiring strict low-density lipoprotein cholesterol management with proprotein convertase subtilisin/kexin 9 inhibitor after coronary artery bypass grafting.
    Abe T, Sato K, Sekiguchi H, Nakao M, Im J, Sakai A, Yamamoto T, Shoda M, Hagiwara N.
    J Cardiol Cases; 2021 Sep 03; 24(3):126-130. PubMed ID: 34466176
    [Abstract] [Full Text] [Related]

  • 34. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.
    Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V.
    J Clin Lipidol; 2018 Sep 03; 12(5):1141-1145. PubMed ID: 30318064
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 03; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ, Shah P, Goldenberg N, Prince M, Lee K, Jetty V, Kumar A, Goldenberg M, Wang P.
    Lipids Health Dis; 2016 Mar 12; 15():55. PubMed ID: 26968977
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.